Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.

Enokida H, Yamada Y, Tatarano S, Yoshino H, Yonemori M, Sakaguchi T, Nishimura H, Eura R, Nakagawa M.

Jpn J Clin Oncol. 2020 Jan 24;50(1):66-72. doi: 10.1093/jjco/hyz138.

PMID:
31665352
2.

Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.

Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.

Int J Clin Oncol. 2015 Oct;20(5):1018-25. doi: 10.1007/s10147-015-0802-y. Epub 2015 Feb 15.

PMID:
25681879
3.

Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.

Koie T, Ohyama C, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, Kamimura N.

Prostate Cancer Prostatic Dis. 2012 Dec;15(4):397-401. doi: 10.1038/pcan.2012.29. Epub 2012 Aug 14.

PMID:
22890389
4.

Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.

Hagiwara K, Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Tobisawa Y, Yoneyama T.

Int Urol Nephrol. 2017 May;49(5):811-816. doi: 10.1007/s11255-017-1546-6. Epub 2017 Feb 17.

PMID:
28213801
5.

Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.

Fujita N, Koie T, Ohyama C, Tanaka Y, Soma O, Matsumoto T, Yamamoto H, Imai A, Tobisawa Y, Yoneyama T, Hatakeyama S, Hashimoto Y.

Int J Clin Oncol. 2017 Dec;22(6):1087-1093. doi: 10.1007/s10147-017-1160-8. Epub 2017 Jul 5.

PMID:
28681153
6.

Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.

Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Aoki M, Takai Y.

World J Surg Oncol. 2014 Apr 30;12:134. doi: 10.1186/1477-7819-12-134.

7.

Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.

Narita S, Nara T, Kanda S, Numakura K, Saito M, Inoue T, Satoh S, Nanjo H, Tsuchiya N, Mitsuzuka K, Koie T, Kawamura S, Ohyama C, Tochigi T, Arai Y, Habuchi T.

Clin Genitourin Cancer. 2019 Feb;17(1):e113-e122. doi: 10.1016/j.clgc.2018.09.019. Epub 2018 Sep 27.

PMID:
30391137
8.

Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.

Matsumoto T, Hatakeyama S, Ookubo T, Mitsuzuka K, Narita S, Inoue T, Yamashita S, Narita T, Koie T, Kawamura S, Tochigi T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C.

Med Oncol. 2017 Oct 31;34(12):190. doi: 10.1007/s12032-017-1050-y.

PMID:
29090390
9.

The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.

Narita T, Koie T, Ookubo T, Mitsuzuka K, Narita S, Yamamoto H, Inoue T, Hatakeyama S, Kawamura S, Tochigi T, Habuchi T, Arai Y, Ohyama C.

Med Oncol. 2017 Jan;34(1):1. Epub 2016 Nov 26.

PMID:
27889880
10.

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.

Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T.

World J Surg Oncol. 2012 Jan 4;10:1. doi: 10.1186/1477-7819-10-1.

11.

Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution.

Fujita N, Koie T, Hashimoto Y, Narita T, Tobisawa Y, Tanaka T, Noro D, Oikawa M, Hagiwara K, Yoneyama T, Imai A, Yamamoto H, Hatakeyama S, Yoneyama T, Ohyama C.

Int Urol Nephrol. 2018 Nov;50(11):1999-2005. doi: 10.1007/s11255-018-1985-8. Epub 2018 Sep 18.

PMID:
30229466
12.
13.

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

Hirano D, Nagane Y, Satoh K, Mochida J, Sugimoto S, Ichinose T, Takahashi S, Maebayashi T, Saitoh T.

Int Urol Nephrol. 2010 Mar;42(1):81-8. doi: 10.1007/s11255-009-9580-7. Epub 2009 May 16.

PMID:
19449118
14.
15.

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.

Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P.

BJU Int. 2007 Aug;100(2):274-80. Epub 2007 Mar 12. Erratum in: BJU Int. 2007 Aug;100(2):480. Sperandio, Paolo [corrected to Sperandio, Paola].

16.

Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.

Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, Karakiewicz PI, Graefen M, Schwarz R, Kr├╝ll A, Tilki D.

Urol Oncol. 2016 Mar;34(3):119.e11-8. doi: 10.1016/j.urolonc.2015.09.012. Epub 2015 Oct 23.

PMID:
26602027
17.

Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.

Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, Suardi N, Montorsi F, Briganti A, Rocco B, Mottrie A.

Eur Urol. 2017 Feb;71(2):249-256. doi: 10.1016/j.eururo.2016.05.008. Epub 2016 May 18.

PMID:
27209538
18.

Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.

Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, Vickers AJ, Bernie A, Konety BR, Kelly WK, Eastham JA.

BJU Int. 2015 Jul;116(1):50-6. doi: 10.1111/bju.12676. Epub 2015 Apr 17.

19.

Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.

Castelli T, Russo GI, Favilla V, Urzi D, Spitaleri F, Reale G, Giardina R, Saita A, Madonia M, Cimino S, Morgia G.

Int Braz J Urol. 2014 May-Jun;40(3):322-9. doi: 10.1590/S1677-5538.IBJU.2014.03.05.

20.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502

Supplemental Content

Support Center